HealthcarePharmaSmall Cap StocksBioTech

Treating Heart Disease Behind Sudden Death in Young People | David Elsey

The Deep Dive
The Deep Dive•Apr 16, 2026

Why It Matters

Successful trials would give Cardiol a first‑in‑class anti‑inflammatory therapy for rare cardiac diseases and a scalable heart‑failure drug, unlocking a billion‑dollar market and significant upside for investors.

Key Takeaways

  • •Cardiol Therapeutics advancing Maverick Phase III trial for recurrent pericarditis.
  • •Archer Phase II data shows 3‑month LV mass reduction comparable to Entresto.
  • •CRD38, a once‑monthly formulation, targets chronic inflammation in heart failure.
  • •Company raised $31 million, runway extends to Q4 2027 for key milestones.
  • •Potential U.S. market exceeds $1 billion, driving partnership and acquisition interest.

Summary

Cardiol Therapeutics used the interview to detail progress on its Maverick Phase III trial for recurrent pericarditis and the Archer Phase II study in myocarditis, while previewing its next‑generation drug CRD38 aimed at chronic heart‑failure inflammation.

The Archer data, presented at the European Society of Cardiology meeting, showed a statistically significant reduction in left‑ventricular mass within three months—an effect the company likened to that of blockbuster GLP‑1 therapies and Novartis’ Entresto. Maverick has now passed the 50 % enrollment threshold, enrolling leading centers such as Mayo, Mass General and Johns Hopkins, positioning the trial for a near‑term readout.

Dr. Les Cooper of the Mayo Clinic highlighted the LV‑mass improvement as the first structural reversal observed in myocarditis patients. David Elsey emphasized that current pericarditis and myocarditis treatments rely on steroids, injectable biologics or off‑label drugs that are costly and toxic, underscoring the unmet need his pipeline seeks to fill.

If Maverick delivers positive Phase III results, Cardiol expects a U.S. market opportunity exceeding $1 billion and a pathway to a new drug application. The forthcoming CRD38 monthly formulation could open a multi‑billion heart‑failure market, accelerating partnership talks and potentially making the company an attractive acquisition target.

Original Description

Register here for The 2026 Rule Symposium on Natural Resource Investing:
#cardio #biotechnology #médecine #stockmarket #finance
In this conversation with David Elsley, President and CEO of Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL), we discuss the company’s progress in inflammatory heart disease, including momentum in the Phase 3 MAVERIC trial for recurrent pericarditis, new data from the Phase 2 ARCHER program in myocarditis, and why the latest results could have implications far beyond rare disease. David explains what makes these conditions so difficult to treat, why the current standard of care remains limited, and how Cardiol is positioning both its lead oral therapy and its next-stage once-monthly heart failure asset for major value-creating milestones ahead.
What makes this discussion stand out is that it is not just about one trial update. David lays out how the company is moving from rare cardiac disease toward much larger commercial opportunities, why the recent myocarditis data matters scientifically, and how Cardiol’s balance sheet now supports key catalysts through Phase 3 readout, regulatory work, and the advance of CRD38 into clinical development. If you value real conversations that break down biotech stories without the usual noise, subscribe to the channel and share this with someone else following the market. That support helps us keep bringing on guests like this and asking the questions that matter.
Catch our full suite of content below:
====================================================================
Looking for better insights on the markets? The Deep Dive Spotlights is providing exclusive industry insights from executives, insiders, technicians, specialists and more.
We're upgrading our Canadian small cap coverage from written to visual, hitting investors with a double dose of market insights to provide a special look into just what's happening in the Canadian public markets.
=================================================================
TheDeepDive.ca Team
Writers: Jordan Lutz & Steve Hyland
Producer: Chriz Rayos
Host: Steve Hyland
Post Production Head: Oveja Rayos
=================================================================
Disclaimer:
Not a recommendation to buy or sell securities. Always do additional research and consult a professional before purchasing a security. The Deep Dive and its affiliates hold no licenses.
00:00 Introduction
00:33 The Heart Drug Story Taking Shape
02:31 The Data That Got Attention
04:25 Why the Trial Is Gaining Speed
05:55 The Drug With the Bigger Market
08:10 The Treatment Gap No One Has Solved
10:05 Balance Sheet Strength and Partnering Leverage
11:39 What Has to Happen Next

Comments

Want to join the conversation?

Loading comments...